We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-4.45%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.08B
AUM Growth
+$322M
Cap. Flow
+$648M
Cap. Flow %
21%
Top 10 Hldgs %
37.4%
Holding
321
New
89
Increased
78
Reduced
45
Closed
96

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$32M
2
CCCC icon
C4 Therapeutics
CCCC
+$14.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.1M
4
AMRS
Amyris Inc.
AMRS
+$11M
5
TECH icon
Bio-Techne
TECH
+$10.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$14.1M
2
DXCM icon
DexCom
DXCM
+$14.1M
3
ICUI icon
ICU Medical
ICUI
+$14M
4
LIVN icon
LivaNova
LIVN
+$12.2M
5
OLPX
Olaplex Holdings
OLPX
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 24.06%
2 Materials 0.35%
3 Industrials 0.17%
4 Consumer Discretionary 0.07%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
226
CALL
Adaptive Biotechnologies
ADPT
$4.02B
– –
-161,800
Closed -$4.54M
AHCO icon
227
PUT
AdaptHealth
AHCO
$770M
– –
-98,600
Closed -$2.41M
ALC icon
228
PUT
Alcon
ALC
$35.6B
– –
-108,100
Closed -$9.42M
AMN icon
229
CALL
AMN Healthcare
AMN
$1.26B
– –
-150,000
Closed -$18.4M
AMRN
230
Amarin Corp
AMRN
$297M
– –
-9,857
Closed -$664K
APRE icon
231
Aprea Therapeutics
APRE
$8.46M
– –
-21,693
Closed -$1.25M
ARDX icon
232
Ardelyx
ARDX
$1.03B
– –
-229,916
Closed -$253K
BEAM icon
233
Beam Therapeutics
BEAM
$2.76B
– –
-13,978
Closed -$917K
BHC icon
234
CALL
Bausch Health
BHC
$2.32B
– –
-98,600
Closed -$2.72M
BNTX icon
235
BioNTech
BNTX
$23.3B
– –
-9,857
Closed -$2.54M
CMPS
236
CALL
Compass Pathways
CMPS
$1.97B
– –
-28,300
Closed -$625K
COO icon
237
PUT
Cooper Companies
COO
$15B
– –
-158,000
Closed -$16.5M
CRBU icon
238
Caribou Biosciences
CRBU
$169M
– –
-41,932
Closed -$633K
CTMX icon
239
CytomX Therapeutics
CTMX
$760M
– –
-96,905
Closed -$420K
DAL icon
240
PUT
Delta Air Lines
DAL
$59.1B
– –
-197,100
Closed -$7.7M
DHR icon
241
PUT
Danaher
DHR
$145B
– –
-33,840
Closed -$9.87M
DXCM icon
242
DexCom
DXCM
$34.3B
– –
-105,248
Closed -$14.1M
DXCM icon
243
PUT
DexCom
DXCM
$34.3B
– –
-173,200
Closed -$23.3M
ENVB icon
244
Enveric Biosciences
ENVB
$6.24M
– –
-82
Closed -$690K
FATE icon
245
PUT
Fate Therapeutics
FATE
$317M
– –
-48,500
Closed -$2.84M
GYRE icon
246
Gyre Therapeutics
GYRE
$706M
– –
-47,574
Closed -$326K
HOLX
247
PUT
DELISTED
Hologic
HOLX
– –
-75,000
Closed -$5.74M
IDXX icon
248
PUT
Idexx Laboratories
IDXX
$45B
– –
-13,100
Closed -$8.63M
IMCR icon
249
Immunocore
IMCR
$1.77B
– –
-19,071
Closed -$653K
INCY icon
250
Incyte
INCY
$24.5B
– –
-49,278
Closed -$3.62M
8 9
10
11 12

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2022 Portfolio in Review

As of Q1 2022, Pura Vida Investments held 321 positions worth $3.08B, up 12% from $2.76B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $648M of net new capital in Q1 2022, opening 89 new positions and adding to 78 existing holdings. Its largest new stake was Biogen: 147,135 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 30% a quarter earlier, followed by Materials and Industrials.

On the sell side, the largest reduction was ICU Medical, an estimated $14M trimmed.

  • Pura Vida Investments's largest Q1 2022 buy was Biogen: 147,135 shares worth $31M.
  • Pura Vida Investments added most to C4 Therapeutics in Q1 2022, an estimated $14.5M increase.
  • Pura Vida Investments's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $14M.
  • Pura Vida Investments fully exited Natera in Q1 2022, selling an estimated $14.1M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $3.08B portfolio in Q1 2022.
  • Pura Vida Investments opened 89 new positions and closed 96 in Q1 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $3.08B.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.